Ibrutinib

Zanubrutinib induced a superior overall response rate compared with ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to study results.

Acalabrutinib proved noninferior to ibrutinib in terms of PFS and resulted in less cardiotoxicity and fewer discontinuations due to adverse effects in a head-to-head trial among patients with previously treated chronic lymphocytic leukemia.

Research presented at ASH Annual Meeting and Exposition provided an exciting update on many of the underappreciated clinical manifestations of cold agglutinin disease, as well as data on potential new therapeutic interventions.

Acalabrutinib conferred a similar PFS benefit as ibrutinib for adults with previously treated high-risk chronic lymphocytic leukemia, according to topline results of a randomized phase 3 trial.

LOXO-305, a novel non-covalent BTK inhibitor, was active in B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, according to data presented at the ASH Annual Meeting and Exposition.

New data suggest ibrutinib may be able to improve CAR T-cell production when administered before apheresis, according to a presentation at the ASH Annual Meeting and Exposition.

Patients with chronic lymphocytic leukemia with undetectable minimal residual disease after first-line venetoclax plus ibrutinib achieved similar 1-year DFS whether they then received ibrutinib or placebo, according to study results.

A four-factor prognostic model identified patients with chronic lymphocytic leukemia who had poorer survival outcomes with ibrutinib, according to study results published in Journal of Clinical Oncology.

A recent study showed that a healthy diet may reduce the risk for prostate cancer. It was the top story in hematology/oncology last week.

A combination of obinutuzumab, ibrutinib and venetoclax induced deep remissions in patients with treatment-naive or relapsed/refractory chronic lymphocytic leukemia, according to study results published in Journal of Clinical Oncology.